Journal article
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Abstract
BACKGROUND: The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.
METHODS: We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal growth factor …
Authors
Sparano JA; Gray RJ; Ravdin PM; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Goetz MP
Journal
New England Journal of Medicine, Vol. 380, No. 25, pp. 2395–2405
Publisher
Massachusetts Medical Society
Publication Date
June 20, 2019
DOI
10.1056/nejmoa1904819
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAge FactorsAgedAlgorithmsAntineoplastic Agents, HormonalBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalEstrogen AntagonistsFemaleGene Expression ProfilingHumansMiddle AgedNeoplasm Recurrence, LocalPremenopausePrognosisProportional Hazards ModelsProspective StudiesReceptor, ErbB-2Risk FactorsTamoxifen